Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 227239
Proprietary Rights means the Patent Rights and all copyrights, trademarks, industrial designs and other intellectual property rights or benefits (including Know-How) specifically relating to Anti-Idiotype Applications of the B43 Antibody, the B43 Working Cell Bank and the Data, in each case owned or controlled by Licensor, but excluding the Multi-Epitopic Patent Rights;
Data means, as of November 24, 1995 (the effective date of the Original Agreement), the experimental and clinical data and records of Licensor relating to the B43 Antibody, the B43 Working Cell Bank and the product OVAREX(TM) owned by Licensor;
B43 Antibody means the murine antibody MAb B43.13
MAb-B43 relates to anti-idiotype applications.
B43 Working Cell Bank means Licensors murine working hybridoma cell bank B43.13 of the murine hybridoma clone B43.13 such cell bank being produced at the Charles River Laboratories and used in the OVAREX(TM) program as of November 24, 1995 (the effective date of the Original Agreement);
Anti-Idiotype Applications means the induction of anti-idiotype and/or cellular immune response by administration of a formulation containing an antibody, antibody fragment or antibody derivative for the treatment or prevention of disease. Without limiting the generality of the foregoing, Anti-Idiotype Applications specifically includes the administration of the B43 Antibody for therapeutic or prophylactic purposes;
IPSCIO Record ID: 28676
Licensed Technology means, collectively, (j) OvaRexÂ®, BrevaRexÂ®, ProstaRexâ„¢, AR54, and GivaRexâ„¢ their formulations and methods of administration; (k) the Prior Development Technology; (l) Patents, Know-How, and Joint Intellectual Property, (m) all Information relating to those certain antibodies known as OvaRexÂ®, BrevaRexÂ®, ProstaRexâ„¢, AR54, and GivaRexâ„¢ in the course of any work conducted pursuant to this Agreement, and (n) Improvements.
Therapeutic composition that produce an immune response Altered Immunogenicity USA 9/2/98 09/152,698
Therapeutic Binding Agents against MUC-1 antigen and methods of their use BrevaRex USA 8/18/00 09/641,833 & USA 11/26/01 09/994,466
Therapeutic method utilizing antigen-antibody complexation and presentation by dendritic cells-Dendritic Cells.
OvaRex listen (OH-vuh-REX) A monoclonal antibody that is being studied in the treatment of ovarian cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body, including cancer cells. OvaRex binds to the CA-125 antigen, which is found on most ovarian cancer cells. Also called oregovomab.
BrevaRex A phase-II trial, activated murine monoclonal antibody developed for treating tumours expressing MUC-1â€”e.g., breast, prostate, pancreas, renal, lung and colorectal cancers.
ProstaRex(TM) MAb to induce T cells in laboratory studies to a circulating prostate cancer antigen, PSA.
GIVAREX is a product related to gastrointestinal cancer vaccine based on a murine monoclonal antibody and a gastrointestinal cancer pharmaceutical preparations for vaccination consisting of the monoclonal antibody supplied in a proprietary formulation for intravenous, subcutaneous, intraperitoneal or intramuscular injection in humans.
Licensee is involved in the development and commercialization of products potentially useful in the prevention, mitigation and treatment of disease.
IPSCIO Record ID: 27645
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5
4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas
5,286,647 – human-human hybridomas for neoplasms
5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.
5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.
6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions
6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
6,051,693 – CLNH11-specific antibodies
6,090,924 – human-human CLNH5-specific antibodies
6,165,467 – stabilized human monoclonal antibody preparation
The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company